Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2018-02-13 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于签署奥硝唑合作项目补充协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a supplementary agreement for a cooperation project involving the transfer of technology rights and ownership related to a pharmaceutical product (奥硝唑注射液). It details the transaction overview, parties involved, agreement terms, and impact on the company. There is no indication that this is a full financial report, audit report, or earnings release. It is a corporate announcement about a specific transaction or cooperation agreement. The document is not a merger or acquisition filing, but rather a capital/financing update related to the acquisition of rights and technology. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5830 characters) supports it being a detailed announcement rather than a brief notice or regulatory filing.
2018-02-13 Chinese
第六届董事会第十四次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the resolution passed in the 14th extraordinary meeting of the 6th board. It details the signing of a supplementary agreement related to a cooperation project for a pharmaceutical product, including financial terms and ownership rights. The content focuses on a board decision and contractual agreement rather than financial results, audit information, or regulatory filings. There is no indication of it being a full report, earnings release, or management discussion. The document is an official announcement of a board meeting resolution, which fits the category of Board/Management Information (MANG). The document length is short and specific to board decisions, not a report or presentation.
2018-02-13 Chinese
关于控股子公司获得药品GMP证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (611 characters) from Beijing SL Pharmaceutical Co., Ltd. about its controlling subsidiary receiving a GMP certificate from the Henan Food and Drug Administration. It contains no financial data, no detailed report, and no mention of financial results or management changes. It is an official regulatory announcement about a certification related to pharmaceutical production. The document is not a report, transcript, or financial filing but a regulatory announcement about a compliance/certification event. Therefore, it fits best under Regulatory Filings (RNS).
2018-01-31 Chinese
关于第二大股东解除部分股权质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the partial release of pledged shares by the company's second largest shareholder. It details the number of shares released from pledge, dates, and related information about share pledging. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits best under the category of Major Shareholding Notification (MRQ) since it involves significant share ownership and pledge changes by a major shareholder.
2018-01-19 Chinese
关于来那度胺经销权情况的说明
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Beijing SL Pharmaceutical Co., Ltd. regarding a dispute over the distribution rights of a pharmaceutical product (Lenalidomide capsules). It includes historical contract details, agreements, and clarifications about the company's rights and obligations. The document is a formal explanation addressing media reports and clarifying the company's position on a specific business matter. It does not contain financial statements, earnings data, or regulatory certifications. It is not a report of voting results, management changes, or legal proceedings per se, but rather a regulatory announcement clarifying a business dispute and contractual matters. Given the nature and length (3318 characters) and the content focusing on clarifying a business dispute and contractual rights, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-01-10 Chinese
关于第二大股东部分股权质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's second largest shareholder. It details the number of shares pledged, the pledge start date, pledge term, pledgee, and the proportion of shares pledged. There is no financial report, earnings data, or management discussion. The content is about a shareholder's share pledge, which is a capital or financing activity related to the company's shares. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Hence, the classification is CAP with high confidence.
2018-01-05 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.